GE Healthcare partners with Oritain for an independent test that can confirm the country of origin of fetal bovine serum (FBS), a component of biopharmaceutical production.
GE Healthcare and Oritain, a New Zealand-based company specializing in the scientific verification of food origins, have launched an independent test-based traceability program to authenticate the country of origin of fetal bovine serum (FBS), a cell growth supplement used for manufacturing biopharmaceuticals and vaccines. FBS is also used in basic research and drug discovery. The country of origin is important because FBS is used in biomanufacturing, and different countries pose different risk levels for virus contamination. Using FBS from low-risk countries is a priority in biomanufacturing.
GE is currently traceability-certified by the International Serum Industry Association. To verify that raw serum from Australia, New Zealand, and the United States is from that country of origin, GE will also put its sera products through a testing process that goes beyond industry-standard traceability practices. With GE’s new testing program, Oritain will perform independent testing on FBS batch samples from Australia, New Zealand, and the US. Oritain’s scientific traceability method does not rely on paper or labels, but rather authenticates the origin of the product itself, according to Oritain in a company press release.
Source: GE
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.